Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CUE-102 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Cue Biopharma

    • Most Recent Events

    • 12 Nov 2024 According to a Cue Biopharma media release, the company to discuss data presented at the SITC 2024 in a fireside chat at the Stifel 2024 Healthcare Conference being held in New York, NY, November 18-19, 2024.
    • 08 Nov 2024 According to a Cue Biopharma media release, data from this study was presented on 9 November at the Society for Immunotherapy of Cancers 39th Annual Meeting (SITC 2024) being held in Houston, Texas
    • 04 Oct 2024 According to a Cue Biopharma media release, data from this study will be presented at the Society for Immunotherapy of Cancers 39th Annual Meeting (SITC 2024) will be held in Houston, Texas, on Saturday, November 9, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top